Wanebo H J, Koness R J, MacFarlane J K, Eilber F R, Byers R M, Elias E G, Spiro R H
Department of Surgical Oncology, Brown University, Providence, Rhode Island.
Head Neck. 1992 Jan-Feb;14(1):1-7. doi: 10.1002/hed.2880140102.
A Head and Neck Sarcoma Registry was established by the Society of Head and Neck Surgeons to review treatment results of a rare tumor by surgeons with special interest in this anatomic site. Two hundred fourteen patients were analyzed. There were 194 adult tumors and 20 pediatric tumors. The major sites included parotid and neck, 20%; face and forehead, 18%; maxilla and palate, 13%; scalp, 12%; mandible, 11%; paranasal sinuses, 7%; larynx, 2%; and oral cavity, 5%. Eighty-four percent were resectable. The disease-free survival was 56%; overall survival was 70% at 5 years. Major determinants of survival were adequacy of resection (margins free of tumor) and tumor type. Survival differed according to tumor cell type (tumor grade was not available). Patients with chondrosarcoma and dermatofibrosarcoma had survival approaching 100%. Patients with malignant fibrous histiocytoma (MFH) and fibrosarcoma (FSA) had intermediate survival of 60% to 70%. The worst survival, less than 50% at 5 years, occurred in patients with osteosarcoma, angiosarcoma, and rhabdomyosarcoma in decreasing order. This suggests a rationale for identifying high-risk patients for prospective adjuvant protocols. This study emphasizes the value of recording uncommon tumors to provide relevant information for future study and possibly therapy.
头颈外科医师协会设立了一个头颈肉瘤登记处，以评估对该解剖部位有特殊兴趣的外科医生对一种罕见肿瘤的治疗结果。对214名患者进行了分析。其中有194例成人肿瘤和20例儿童肿瘤。主要发病部位包括腮腺和颈部，占20%；面部和前额，占18%；上颌骨和腭部，占13%；头皮，占12%；下颌骨，占11%；鼻窦，占7%；喉部，占2%；口腔，占5%。84%的肿瘤可切除。无病生存率为56%；5年总生存率为70%。生存的主要决定因素是切除的充分性（切缘无肿瘤）和肿瘤类型。生存情况因肿瘤细胞类型而异（肿瘤分级数据不可用）。软骨肉瘤和皮肤纤维肉瘤患者的生存率接近100%。恶性纤维组织细胞瘤（MFH）和纤维肉瘤（FSA）患者的中期生存率为60%至70%。骨肉瘤、血管肉瘤和横纹肌肉瘤患者的生存率最差，5年生存率不到50%，且依次递减。这为确定前瞻性辅助治疗方案的高危患者提供了理论依据。这项研究强调了记录罕见肿瘤以提供未来研究及可能的治疗相关信息的价值。
